On Friday, Spyre Therapeutics Inc (NASDAQ: SYRE) opened lower -6.49% from the last session, before settling in for the closing price of $24.02. Price fluctuations for SYRE have ranged from $20.07 to $47.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -37.38%. Company’s average yearly earnings per share was noted 91.27% at the time writing. With a float of $50.01 million, this company’s outstanding shares have now reached $51.40 million.
The extent of productivity of a business whose workforce counts for 30 workers is very important to gauge. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Spyre Therapeutics Inc is 14.81%, while institutional ownership is 82.01%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.27% per share during the next fiscal year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Check out the current performance indicators for Spyre Therapeutics Inc (SYRE). In the past quarter, the stock posted a quick ratio of 7.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.99 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
The latest stats from [Spyre Therapeutics Inc, SYRE] show that its last 5-days average volume of 0.58 million was superior to 0.56 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 36.72%. Additionally, its Average True Range was 1.58.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 4.61%, which indicates a significant decrease from 19.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.55% in the past 14 days, which was lower than the 61.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.11, while its 200-day Moving Average is $30.20. Now, the first resistance to watch is $23.61. This is followed by the second major resistance level at $24.77. The third major resistance level sits at $25.77. If the price goes on to break the first support level at $21.45, it is likely to go to the next support level at $20.45. Assuming the price breaks the second support level, the third support level stands at $19.29.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are currently 51,431K shares outstanding in the company with a market cap of 1.32 billion. Presently, the company’s annual sales total 890 K according to its annual income of -338,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -69,030 K.
